Premium
Clinical 24 month experience of the first MRgFUS Unit for treatment of uterine fibroids in Australia
Author(s) -
Dobrotwir Andrew,
Pun Emma
Publication year - 2012
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/j.1754-9485.2012.02376.x
Subject(s) - medicine , uterine fibroids , sss* , quality of life (healthcare) , magnetic resonance imaging , gynecology , radiology , nursing
Aim: To describe and evaluate treatment of uterine fibroids using Magnetic Resonance Guided Focused Ultrasound (MRgFUS) during its first 24 months of use at The Royal Women's Hospital Melbourne. Methods: One hundred Victorian women were treated with MRgFUS using the ExAblate 2000 system. Treatment outcomes based on fibroid volume shrinkage measured at 4 and 12 months post‐treatment and symptom severity score assessment (Symptom Severity Score Quality of Life – SSS‐QOL) pre‐ and post‐ (4–6 weeks, 4, 6 and 12 months) treatment. Results: Mean non‐perfused volume of the treated fibroids were 67% ± 25% ( n = 100) immediately post‐treatment. At 4 months post‐treatment, the treated fibroids demonstrated an average volume reduction of 29% ± 32% ( n = 74) and at 12 months 38% ± 45% ( n = 32). Mean symptom severity scores (SSS‐QOL) improved by 51% from 59 ± 21 ( n = 97) at baseline to 29 ± 17 ( n = 36) by 12 months. Conclusion: From our experience, we believe there is a role for MRgFUS in the treatment of uterine fibroids in selected women.